ANI Pharmaceuticals' (ANIP) shares were nearly 1% lower Monday after the drug maker said it has completed its acquisition of Alimera Sciences (ALIM).
ANI Pharmaceuticals said it continues to expect the transaction to drive high single-digit to low double-digit accretion in its adjusted non-GAAP earnings per share in 2025 with "substantially higher accretion thereafter."
The deal also should deliver an extra $35 million to $38 million in adjusted non-GAAP earnings before interest, taxes, depreciation and amortization in 2025, including around $10 million in expected cost synergies, the company said.
Price: 57.93, Change: -0.58, Percent Change: -0.99
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。